Oric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 10,720 Shares of Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli sold 10,720 shares of Oric Pharmaceuticals stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $9.06, for a total value of $97,123.20. Following the completion of the sale, the chief financial officer directly owned 68,148 shares in the company, valued at $617,420.88. This represents a 13.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Dominic Piscitelli also recently made the following trade(s):

• On Monday, October 6th, Dominic Piscitelli sold 11,000 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $14.52, for a total value of $159,720.00.

Oric Pharmaceuticals Stock Up 1.3%

Shares of NASDAQ:ORIC traded up $0.11 during mid-day trading on Thursday, reaching $8.33. 153,384 shares of the stock were exchanged, compared to its average volume of 1,170,183. The company has a market cap of $811.26 million, a P/E ratio of -4.80 and a beta of 1.32. Oric Pharmaceuticals, Inc. has a one year low of $3.90 and a one year high of $14.93. The stock’s 50 day simple moving average is $11.94 and its 200-day simple moving average is $10.98.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Thursday, November 13th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.08. Analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ORIC. Vanguard Group Inc. raised its holdings in shares of Oric Pharmaceuticals by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 3,215,887 shares of the company’s stock valued at $17,945,000 after purchasing an additional 12,098 shares during the period. Swiss National Bank increased its position in Oric Pharmaceuticals by 9.6% during the first quarter. Swiss National Bank now owns 68,400 shares of the company’s stock worth $382,000 after buying an additional 6,000 shares during the last quarter. Invesco Ltd. raised its stake in Oric Pharmaceuticals by 68.7% in the first quarter. Invesco Ltd. now owns 40,419 shares of the company’s stock valued at $226,000 after buying an additional 16,461 shares during the period. Nuveen LLC bought a new stake in Oric Pharmaceuticals in the first quarter valued at approximately $935,000. Finally, American Century Companies Inc. lifted its position in shares of Oric Pharmaceuticals by 4.4% in the first quarter. American Century Companies Inc. now owns 112,628 shares of the company’s stock valued at $628,000 after buying an additional 4,766 shares during the last quarter. Institutional investors own 95.05% of the company’s stock.

Analyst Ratings Changes

ORIC has been the topic of a number of research reports. Wolfe Research initiated coverage on shares of Oric Pharmaceuticals in a research report on Tuesday, November 18th. They issued a “peer perform” rating on the stock. HC Wainwright boosted their price target on shares of Oric Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Friday, November 14th. Citigroup increased their price objective on shares of Oric Pharmaceuticals from $12.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Guggenheim assumed coverage on Oric Pharmaceuticals in a research report on Thursday, September 4th. They issued a “buy” rating and a $18.00 target price on the stock. Finally, JPMorgan Chase & Co. upped their target price on Oric Pharmaceuticals from $17.00 to $20.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $19.67.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.